Biologically Inspired Engineering, synbio, synthetic biology, crispr
Simons Chase 
In June, Repare Therapeutics Inc (RPTX) raised $220 million by offering 11 million shares at $20, the high end of the upwardly revised range of $18 to $20. Repare is a pre-clinical biotech company developing gene therapies for solid tumors based on a synthetic lethality (SL) approach to drug development. The company has advanced a … Read more
The continued adoption of Internet-related equipment, devices, and services in the health industry is expected to drive the market to reach nearly $200 billion by 2024 according to a new report prepared by Laura Wood at Research and Markets. By the end of 2020, it is estimated that there will be 21 billion connected devices … Read more
The Emeryville, CA-based company will offer 7.4 million shares to raise $126 million at $16 to $18 per share, which translates into a fully diluted market value of $1.2 billion. Berkeley Lights is a leading digital cell biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products. … Read more
Amyris, Inc is unique in many ways, but a synthetic biology company with a fifteen year history makes it a rare entity in a new, formative-stage industry. In 2005, Amyris partnered with the Bill & Melinda Gates Foundation to engineer yeast to make artemisinic acid, a precursor of artemisinin, an effective anti-malarial drug. In 2008, … Read more
TWIST Bioscience Corp (symbol: TWST) is a leading and rapidly growing synthetic biology company that has developed a DNA synthesis platform to industrialize the engineering of biology. Twist is an “emerging growth company” as defined in Section 2(a) of the Securities Act of 1933, as amended, as modified by the Jumpstart Our Business Startups Act … Read more